Our findings provide new insights into hypoxia-mediated necroptosis, suggesting that targeting SUMOylation and FADD has the potential to prevent and treat vascular ischemic injury and related cardiovascular diseases. This evidence concerns the gene FADD and cardiovascular disorder.